Cardiotoxicity of T cell immunotherapies - PubMed
3 hours ago
- #immunotherapy
- #cytokine release syndrome
- #cardiotoxicity
- T cell immunotherapies, including CAR T cell therapy, bispecific antibodies, T cell receptor-engineered T cells, and tumour-infiltrating lymphocytes, are emerging as novel cancer treatments.
- Cardiovascular toxicities, such as arrhythmias, myocardial infarction, and heart failure, can occur due to cytokine release syndrome (CRS) triggered by T cell activation.
- The incidence of cardiovascular events is as high as 20% in patients with high-grade CRS.
- This review summarizes the mechanisms, epidemiology, and management of CRS and associated cardiotoxicity from T cell therapies.
- Understanding CAR T cell therapy and other T cell-based treatments is crucial for preventing and managing adverse cardiovascular events.